Slaughter and May, Hong Kong, advised Credit Suisse (Hong Kong) Limited, as manager, in relation to the HK$1.27 billion secondary placing of shares in Genscript Biotech Corporation held by KPCB China Fund, L.P. and KPCB China Founders Fund, L.P. The placing represents approximately 2.6% of the issued share capital of Genscript Biotech Corporation.

Genscript Biotech Corporation is a leading biotech company focusing exclusively on early drug discovery and development services and is listed on the Main Board of the Stock Exchange of Hong Kong Limited.

Contacts

John Moore (partner), Jianhao Zheng (associate), Sarah Tian (associate)